AR077576A2 - Un peptido de telomerasa y composiciones farmaceuticas para el tratamiento contra el cancer que comprenden tales peptidos - Google Patents

Un peptido de telomerasa y composiciones farmaceuticas para el tratamiento contra el cancer que comprenden tales peptidos

Info

Publication number
AR077576A2
AR077576A2 ARP100102596A AR077576A2 AR 077576 A2 AR077576 A2 AR 077576A2 AR P100102596 A ARP100102596 A AR P100102596A AR 077576 A2 AR077576 A2 AR 077576A2
Authority
AR
Argentina
Prior art keywords
telomerase
peptides
pharmaceutical composition
cancer treatment
composition peptide
Prior art date
Application number
Other languages
English (en)
Original Assignee
Gemvax As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19902234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR077576(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gemvax As filed Critical Gemvax As
Publication of AR077576A2 publication Critical patent/AR077576A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un péptido de telomerasa que consiste de entre 9 y 25 aminoácidos en donde el péptido de telomerasa comprende la secuencia de SEQ ID Ns: 2, 3, 4, 9, 10 o 12 a 19, o un fragmento de SEQ ID Ns: 2, 3, 4, 9, 10 o 12 a 19, al menos 8 aminoácidos de longitud, siendo el fragmento capaz de inducir una respuesta de células T. Acido nucleico que lo codifica y sus usos para la preparacion de medicamentos. Composiciones farmacéuticas que los comprenden y métodos para prepararlas. Método para generar linfocitos T capaces de reconocer y destruir células tumorales en mamíferos. Un linfocito T telomerasa especifico.
ARP100102596 1998-07-08 2010-07-15 Un peptido de telomerasa y composiciones farmaceuticas para el tratamiento contra el cancer que comprenden tales peptidos AR077576A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO19983141A NO313834B1 (no) 1998-07-08 1998-07-08 Telomeraseprotein eller -peptider, nukleinsyresekvenser som koder for disse, farmasöytiske sammensetninger inneholdende disseog fremgangsmÕter for Õ fremstille slike farmasöytiskesammensetninger til profylakse mot og behandling av kreft, samt

Publications (1)

Publication Number Publication Date
AR077576A2 true AR077576A2 (es) 2011-09-07

Family

ID=19902234

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990103374 AR020601A1 (es) 1998-07-08 1999-07-12 Peptidos o proteinas de telomerasa para el tratamiento o profilaxis del cancer, composiciones farmaceuticas que incluyen dichos peptidos o proteinas, uso de dicha composicion para la fabricacion de medicamentos y el metodo para generar linfocitos t capaces de reconocer y destruir celulas tumorales c
ARP100102596 AR077576A2 (es) 1998-07-08 2010-07-15 Un peptido de telomerasa y composiciones farmaceuticas para el tratamiento contra el cancer que comprenden tales peptidos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP990103374 AR020601A1 (es) 1998-07-08 1999-07-12 Peptidos o proteinas de telomerasa para el tratamiento o profilaxis del cancer, composiciones farmaceuticas que incluyen dichos peptidos o proteinas, uso de dicha composicion para la fabricacion de medicamentos y el metodo para generar linfocitos t capaces de reconocer y destruir celulas tumorales c

Country Status (20)

Country Link
US (2) US7030211B1 (es)
EP (4) EP1093381B2 (es)
JP (2) JP4618657B2 (es)
CN (1) CN100376290C (es)
AR (2) AR020601A1 (es)
AT (2) ATE458494T1 (es)
AU (1) AU756094B2 (es)
CA (2) CA2336743C (es)
CY (1) CY1109978T1 (es)
CZ (1) CZ303215B6 (es)
DE (2) DE69910580T3 (es)
DK (2) DK1362597T3 (es)
ES (2) ES2341170T5 (es)
HK (1) HK1039068B (es)
HU (1) HU230007B1 (es)
NO (1) NO313834B1 (es)
PL (1) PL203815B1 (es)
PT (2) PT1093381E (es)
TW (1) TWI261617B (es)
WO (1) WO2000002581A1 (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
ATE449851T1 (de) * 1996-10-01 2009-12-15 Geron Corp Menschlicher telomerase reverse transcriptase promoter
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
CA2347067C (en) 1998-03-31 2013-09-17 Geron Corporation Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
AU1331100A (en) * 1998-10-29 2000-05-22 Dana-Farber Cancer Institute Cancer immunotheraphy and diagnosis using universal tumor associated antigens, including htert
EP1171612A2 (en) * 1999-04-09 2002-01-16 Biomira, Inc. Telomerase-specific cancer vaccine
CA2399816A1 (en) 2000-02-15 2001-08-23 Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
EP1257284A4 (en) * 2000-02-15 2005-12-21 Univ California UNIVERSAL VACCINE AND METHOD OF TREATING CANCER USING TELOMERASE REVERSE TRANSCRIPTASE
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
GB0031430D0 (en) 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
GB0105238D0 (en) * 2001-03-02 2001-04-18 Norsk Hydro As Vaccines
GB0112342D0 (en) * 2001-05-21 2001-07-11 Norsk Hydro As Polypeptides
WO2004111075A2 (en) * 2003-03-05 2004-12-23 Dendreon Corporation Alternative reading frame polypeptides for treatment
EP1748067A1 (en) 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
US10767167B2 (en) 2005-07-29 2020-09-08 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
CA2652310A1 (en) * 2006-01-19 2007-08-23 The Regents Of The University Of California Human telomerase reverse transcriptase peptides
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
WO2008010010A1 (en) * 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimization and use of cryptic hla-b7 epitopes for immunotherapy
EP1887084A1 (en) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
JP5207354B2 (ja) * 2008-03-12 2013-06-12 独立行政法人産業技術総合研究所 転写抑制ペプチド及びその遺伝子
JP5787752B2 (ja) * 2008-06-16 2015-09-30 メディオラヌム・ファルマチェウティチ・ソチエタ・ペル・アツィオーニ 抗腫瘍免疫療法
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
US11673914B2 (en) 2009-11-10 2023-06-13 Allegro Pharmaceuticals, LLC Peptide therapies for reduction of macular thickening
CA2780243C (en) 2009-11-10 2019-12-03 Allegro Pharmaceuticals, Inc. Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites
WO2011101173A1 (en) * 2010-02-16 2011-08-25 Oslo University Hospital Hf Polypeptides
FR2960542B1 (fr) * 2010-05-27 2012-08-17 Esther Suzy Arlette Fellous Peptide en tant que medicament, en particulier pour le traitement du cancer
BR112013028914B1 (pt) * 2011-05-09 2022-02-15 Allegro Pharmaceuticals, Inc Uso de um peptídeo inibidor de integrina que consiste em glicinil-arginil-glicinil-cisteico (ácido)-treonil-prolina-cooh para tratar edema macular
EP2847213B1 (en) * 2012-05-11 2018-01-03 KAEL-GemVax Co.,Ltd Anti-inflammatory peptides and composition comprising the same
WO2013169067A1 (ko) 2012-05-11 2013-11-14 주식회사 카엘젬백스 류마티즘 관절염 예방 또는 치료 조성물
US9527888B2 (en) 2012-05-11 2016-12-27 Gemvax & Kael Co., Ltd. Anti-inflammatory peptides and composition comprising the same
EP2873678B8 (en) * 2012-07-11 2024-07-17 Gemvax & Kael Co., Ltd. Conjugate comprising a cell-penetrating peptide and compositions comprising same
US20150125438A1 (en) 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
TWI616530B (zh) * 2012-09-19 2018-03-01 傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物（一）
KR102038487B1 (ko) 2012-09-19 2019-10-30 주식회사 젬백스앤카엘 텔로머라제 펩티드를 포함하는 항균 또는 항진균용 조성물
CN110028554B (zh) * 2012-09-19 2023-04-07 珍白斯凯尔有限公司 细胞穿透性肽、包含该肽的缀合物、及包含该缀合物的组合物
WO2014046490A1 (ko) * 2012-09-19 2014-03-27 주식회사 카엘젬백스 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
ES2956510T3 (es) * 2012-09-19 2023-12-22 Gemvax & Kael Co Ltd Péptido penetrante celular, conjugado que lo comprende y composición que comprende el conjugado
KR102166542B1 (ko) 2012-09-28 2020-10-16 주식회사 젬백스앤카엘 줄기세포 검출을 위한 텔로머라제 유래 펩티드 및 조영물질의 컨쥬게이트 및 이를 포함하는 조영제
CN102875657B (zh) * 2012-10-22 2014-04-09 南京工业大学 一种制备端粒酶多肽疫苗的方法
KR102106756B1 (ko) 2012-12-13 2020-05-06 주식회사 젬백스앤카엘 자외선에 의한 피부 손상 예방 또는 치료용 조성물
KR102093093B1 (ko) 2012-12-13 2020-03-25 주식회사 젬백스앤카엘 피부 노화 개선용 조성물
EP2987497B1 (en) * 2013-04-19 2018-12-26 Gemvax & Kael Co., Ltd. Composition for treating and preventing ischemic damage
TWI634210B (zh) * 2013-05-03 2018-09-01 傑姆維克斯＆凱爾有限公司 抑制熱休克蛋白質表現之胜肽及包含其之組成物
AU2014275610B2 (en) * 2013-06-07 2018-06-14 Gemvax & Kael Co., Ltd. Biological markers useful in cancer immunotherapy
KR102166545B1 (ko) * 2013-06-21 2020-10-16 주식회사 젬백스앤카엘 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
CN105531284B (zh) * 2013-07-12 2021-03-23 珍白斯凯尔有限公司 细胞穿透肽和包含其的缀合物
KR102204476B1 (ko) * 2013-08-14 2021-01-19 주식회사 젬백스앤카엘 다발성 경화증 치료 및 예방용 조성물
GB201315946D0 (en) * 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
BR112016008331B1 (pt) * 2013-10-23 2023-01-31 Sang Jae Kim Composição para tratar e prevenir hiperplasia prostática benigna (bhp) e uso da dita composição para tratar e prevenir bhp
CN105848667B (zh) * 2013-11-22 2020-05-19 珍白斯凯尔有限公司 具有血管生成抑制活性的肽和包含所述肽的组合物
KR102106757B1 (ko) * 2013-11-29 2020-05-06 주식회사 젬백스앤카엘 난소 동결 보존용 펩티드 및 이를 포함하는 조성물
KR20160097244A (ko) * 2013-12-10 2016-08-17 주식회사 젬백스앤카엘 항산화 효과를 가지는 펩티드 및 이를 포함하는 조성물
EP3085380B1 (en) * 2013-12-17 2020-06-17 Gemvax & Kael Co., Ltd. Composition for treating prostate cancer
KR102166549B1 (ko) 2014-01-10 2020-10-16 주식회사 젬백스앤카엘 혈뇌장벽 투과성 펩티드 및 이를 포함하는 컨쥬게이트
KR101503341B1 (ko) * 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
CN106456697B (zh) 2014-04-11 2019-12-17 珍白斯凯尔有限公司 具有纤维化抑制活性的肽和含有其的组合物
WO2015170790A1 (ko) * 2014-05-09 2015-11-12 주식회사 카엘젬백스 허혈성 손상 치료 및 예방용 조성물
EP3138399B1 (en) 2014-04-30 2023-09-06 Gemvax & Kael Co., Ltd. Composition for organ, tissue, or cell transplantation, kit, and transplantation method
CN105504017B (zh) * 2014-05-29 2019-05-03 天津久益生物科技有限公司 一种治疗癌症的肽变体及其应用
KR102166543B1 (ko) * 2014-06-02 2020-10-16 주식회사 젬백스앤카엘 켈로이드 억제용 조성물 및 그 억제 방법
KR102413243B1 (ko) * 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
KR102397510B1 (ko) * 2014-12-23 2022-05-13 주식회사 젬백스앤카엘 난소 기능 보존용 펩티드 및 이를 포함하는 조성물
CN107405380B (zh) * 2015-02-27 2021-04-20 珍白斯凯尔有限公司 用于预防听觉损伤的肽及其包含该肽的组合物
KR20180004752A (ko) 2015-05-26 2018-01-12 주식회사 젬백스앤카엘 신규 펩티드 및 이를 포함한 조성물
JP6923453B2 (ja) * 2015-07-02 2021-08-18 ジェムバックス アンド カエル カンパニー，リミティド 抗ウイルス活性効能を有するペプチド及びこれを含む組成物
KR20170054310A (ko) * 2015-11-09 2017-05-17 주식회사 젬백스앤카엘 텔로머라제 유래 펩티드를 포함하는 수지상세포 치료제 및 면역 치료제, 및 이를 사용하는 치료방법
EP3441082B1 (en) 2016-04-07 2023-06-21 Gemvax & Kael Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
AU2018206015B2 (en) 2017-01-06 2019-05-30 Eutilex Co., Ltd. Anti-human 4-1 BB antibodies and use thereof
US11771749B2 (en) 2017-02-03 2023-10-03 The Medical College Of Wisconsin, Inc. KRAS peptide vaccine compositions and method of use
JP2020522480A (ja) 2017-06-02 2020-07-30 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ 個別化された犬用癌ワクチンを作製する方法
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
JP2023521895A (ja) * 2020-04-17 2023-05-25 リネージ セル セラピューティクス インコーポレイテッド テロメラーゼ逆転写酵素に特異的なｍｈｃ拘束性免疫原性ペプチド、その複合体コンジュゲート、およびそれらを使用する方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
ES2530769T3 (es) * 1994-06-14 2015-03-05 Univ Leland Stanford Junior Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
US5968506A (en) 1995-08-04 1999-10-19 Geron Corporation Purified telomerase
PT880360E (pt) * 1996-02-12 2003-02-28 Ml Lab Plc Novos metodos de vacinacao e consequentes vacinas que compreendem um acido nucleico que codifica um primeiro epitopo e um peptido que contem um segundo epitopo
WO1997035619A1 (en) 1996-03-28 1997-10-02 Genitrix, L.L.C. Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
WO1998001493A1 (en) * 1996-07-08 1998-01-15 Jvs-Polymers Oy High impact strength biodegradable material
US5770422A (en) 1996-07-08 1998-06-23 The Regents Of The University Of California Human telomerase
ATE449851T1 (de) * 1996-10-01 2009-12-15 Geron Corp Menschlicher telomerase reverse transcriptase promoter
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
CA2347067C (en) 1998-03-31 2013-09-17 Geron Corporation Dendritic cell vaccine containing telomerase reverse transcriptase for the treatment of cancer
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants

Also Published As

Publication number Publication date
CN100376290C (zh) 2008-03-26
ATE458494T1 (de) 2010-03-15
EP1362597B2 (en) 2014-06-25
DE69942072D1 (de) 2010-04-08
US7030211B1 (en) 2006-04-18
EP1093381B2 (en) 2009-07-22
CA2336743C (en) 2011-10-11
ATE247484T1 (de) 2003-09-15
DK1093381T3 (da) 2003-09-08
AR020601A1 (es) 2002-05-22
ES2200526T5 (es) 2009-12-11
CN1313773A (zh) 2001-09-19
JP4618657B2 (ja) 2011-01-26
NO313834B1 (no) 2002-12-09
AU756094B2 (en) 2003-01-02
EP2258383A2 (en) 2010-12-08
PT1362597E (pt) 2010-04-14
EP2258383A3 (en) 2011-05-11
PT1093381E (pt) 2004-01-30
US20060106196A1 (en) 2006-05-18
US7794723B2 (en) 2010-09-14
CA2748996A1 (en) 2000-01-20
ES2341170T5 (es) 2014-09-09
NO983141L (no) 2000-01-10
CZ303215B6 (cs) 2012-05-30
JP5491315B2 (ja) 2014-05-14
HUP0104889A3 (en) 2004-04-28
CZ200137A3 (en) 2001-06-13
DE69910580D1 (de) 2003-09-25
EP2316476B1 (en) 2015-11-25
EP2316476A2 (en) 2011-05-04
EP2258383B1 (en) 2016-03-09
EP2316476A3 (en) 2011-09-14
HUP0104889A2 (hu) 2002-04-29
EP1362597A1 (en) 2003-11-19
PL203815B1 (pl) 2009-11-30
DK1362597T3 (da) 2010-06-14
EP1362597B1 (en) 2010-02-24
ES2341170T3 (es) 2010-06-16
DE69910580T3 (de) 2009-11-26
JP2002520293A (ja) 2002-07-09
JP2010252810A (ja) 2010-11-11
PL345541A1 (en) 2001-12-17
AU4534099A (en) 2000-02-01
HK1039068A1 (en) 2002-04-12
CA2336743A1 (en) 2000-01-20
CY1109978T1 (el) 2014-09-10
EP1093381B1 (en) 2003-08-20
DK1093381T4 (da) 2009-09-21
EP1093381A1 (en) 2001-04-25
HK1039068B (zh) 2009-02-06
TWI261617B (en) 2006-09-11
HU230007B1 (en) 2015-04-28
DE69910580T2 (de) 2004-06-24
ES2200526T3 (es) 2004-03-01
WO2000002581A1 (en) 2000-01-20

Similar Documents

Publication Publication Date Title
AR077576A2 (es) Un peptido de telomerasa y composiciones farmaceuticas para el tratamiento contra el cancer que comprenden tales peptidos
ES2193145T3 (es) Proteinas procoagulants quimericas.
EA200500644A1 (ru) Высокоэффективные способные к слиянию везикулы, способ их получения и фармацевтическая композиция, их содержащая
ES2147553T3 (es) Vectores virales recombinantes para la expresion en unas celulas musculares.
AR062300A2 (es) Polipeptido que comprende una porcion inmunogenica de una proteina de prostata o su variante, molecula de adn, vector de expresion, celula huesped composicion farmaceutica, vacuna uso de dichas composiciones y vacunas para preparar medicamentos y proteina de fusion
BRPI0113477B8 (pt) proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula
AR017866A1 (es) Metodo para incrementar las inmunorespuestas de vacunas de acidos nucleicos, composiciones farmaceuticas de aplicacion en dicho metodo, procedimientopara preparar dichas composiciones y vacunas utilizadas en dicho metodo.
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
ATE466948T1 (de) Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle
CL2019003409A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
ES2071315T3 (es) Proteasa especifica de ubiquitina.
MX9306147A (es) Composicion farmaceutica para inhibir el crecimiento de celulas tumorales.
CO4650046A1 (es) Metodo para la sintesis de analogos de la hormona paratiroidea y del peptido relacionado con la hormona paratiroidea
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
AR006813A1 (es) Peptidos consistentes en 16 a 55 residuos de aminoacido, composicion farmaceutica que comprende a por lo menos uno de dichos peptidos, metodo dediagnostico para la deteccion de celulas t auto-reactivas activadas que utiliza a por lo menos uno de tales peptidos y equipo para pruebas utilizado en dicho
NO20032818D0 (no) Polypeptider
BR9811850A (pt) Expressão recombinante de peptìdeo c de insulina
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
BR9710849A (pt) Vacina contendo uma peróxi-redoxina e/ou uma beta-tubulina.
BR0303362A (pt) Composição e método para melhorar uma resposta imune em um animal, método para distribuir uma proteìna de carga em uma célula de animal, célula viva geneticamente modificada, e, método para a construção de uma proteìna de fusão para melhorar a resposta imune em um animal
AR014884A1 (es) Uso de un conjugado de angiotensina inmunogenico y composicion farmaceutica
ES2308850T3 (es) Anticuerpos para antigenos de celulas de langerhans de mamiferos y sus usos.
AR012744A1 (es) Molecula de acido nucleico que codifica una proteina vinculadora de sucrosa, proteina vinculadora de sucrosa y metodo para producir una proteinavinculadora de sucrosa.
ES2169995B1 (es) Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno.
ES2160807T3 (es) Fragmento de adn que codifica la oxidasa de d-aminoacidos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure